Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): First case report

Reem Abdwani, Arif Ali Kolethekkat, Rashid Al Abri*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


To report the first case of refractory relapsing polychondritis in a child who was treated with the biological agent, rituximab, an antiCD20 monoclonal antibody. The case is reported with a review of the literature on the use of biological agents in the treatment of refractory relapsing polychondritis. A 10-year-old boy presented with relapsing polychondritis who was treated initially with prednisolone and methotrexate. As there was no response to the treatment, anti TNF antagonist infliximab was given but with a failed response. A subsequent therapy with rituximab produced significant clinical remission with no recurrence at 1 year. Relapsing polychondritis unresponsive to primary treatment modalities but treated with various biological agents in adult have been well described in adults but not reported in children age below 13 yrs. Hence we present this case report. Biological agents such as rituximab has promising role in children when primary treatment fails as reported in our case.

Original languageEnglish
Pages (from-to)1061-1064
Number of pages4
JournalInternational Journal of Pediatric Otorhinolaryngology
Issue number7
Publication statusPublished - Jul 2012
Externally publishedYes


  • Children
  • Refractory
  • Relapsing polychondritis
  • Rituximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Otorhinolaryngology


Dive into the research topics of 'Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): First case report'. Together they form a unique fingerprint.

Cite this